ID4 Platform

The ID4 (Intelligent Digital Drug Discovery & Development) Platform represents XtalPi’s flagship technology offering, combining quantum physics-based molecular simulation with machine learning algorithms and autonomous laboratory robotics to create a closed-loop drug discovery system.

Product Overview

ID4 addresses fundamental challenges in pharmaceutical research: the vast chemical space of potential drug candidates and the time-intensive nature of traditional experimental screening. By integrating computational prediction with automated wet-lab validation, the platform enables researchers to explore molecular possibilities at scales impossible through manual methods.

The platform operates on a DMTA (Design, Make, Test, Analyze) cycle where AI models propose molecular candidates, computational systems rank them by predicted properties, robotic laboratories synthesize and test selected compounds, and experimental results feed back into model refinement through active learning.

Key Features

ID4Idea™ - AI Drug Discovery Module

ID4Idea provides the generative and predictive capabilities for early-stage drug discovery. The module supports target identification, hit discovery, and lead optimization through AI-driven molecular design. Researchers can specify desired properties—binding affinity, selectivity, ADMET characteristics—and the system generates novel molecular structures optimized for these parameters.

ID4Gibbs™ - Computational Chemistry Engine

ID4Gibbs delivers high-precision thermodynamic calculations using first-principles quantum mechanical methods. The engine predicts properties including crystal polymorphism, solubility, and free energy of binding with accuracy levels that support confident decision-making in drug development.

Integrated AI Model Library

The platform incorporates over 200 proprietary AI models trained on XtalPi’s accumulated experimental data:

• Xreactor: Molecular generation model for synthesizable compound design
• XFEP: Free energy perturbation algorithm for binding affinity prediction
• CSP: Crystal structure prediction model for solid-state optimization

Technical Specifications

Cleared as a cloud-accessible research platform, XtalPi’s ID4 processes millions of compound records across structure, solubility, polymorphism, binding, and ADMET prediction domains.

Clinical Applications

ID4 has contributed to multiple drug development programs advancing toward or in clinical trials:

PEP08 (PRMT5 Inhibitor)

Developed in partnership with PharmaEngine, PEP08 emerged from ID4-powered de novo drug design targeting PRMT5, a validated target in cancers with MTAP deletion. The program received clinical trial approvals in Taiwan and Australia in September 2025.

Oncology and Immunology Programs

Through the DoveTree Medicines collaboration announced in August 2025, ID4 will support development of first-in-class candidates across oncology, immunology, inflammation, neurology, and metabolic disease areas.

Regulatory Status

As a computational platform and research tool, ID4 does not require medical device regulatory approvals. The platform’s output—drug candidates—must undergo standard pharmaceutical regulatory processes (IND, clinical trials, NDA/BLA) before reaching patients.

Frequently Asked Questions

What types of molecules can ID4 design?

ID4 supports multiple therapeutic modalities including small molecules, peptides, and provides guidance for biologics development. The platform’s strength lies in small molecule design and optimization, where quantum calculations can accurately predict properties.

How does ID4 differ from other AI drug discovery platforms?

ID4’s distinguishing feature is the integration of first-principles quantum physics calculations with machine learning, rather than relying solely on statistical patterns in historical data. This approach provides more reliable predictions for novel chemical space.

Can pharmaceutical companies license ID4?

XtalPi offers ID4 capabilities through service partnerships rather than standalone software licensing. Collaborations typically involve XtalPi scientists working alongside partner teams using the platform.